BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/16/2016 10:47:00 AM | Browse: 958 | Download: 1219
 |
Received |
|
2016-03-16 08:46 |
|
Peer-Review Started |
|
2016-03-18 10:58 |
|
To Make the First Decision |
|
2016-04-15 08:21 |
|
Return for Revision |
|
2016-04-19 16:19 |
|
Revised |
|
2016-05-06 18:46 |
|
Second Decision |
|
2016-06-27 17:05 |
|
Accepted by Journal Editor-in-Chief |
|
2016-06-28 08:43 |
|
Accepted by Company Editor-in-Chief |
|
2016-07-18 11:05 |
|
Articles in Press |
|
2016-07-18 11:05 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-11-02 10:28 |
|
Publish the Manuscript Online |
|
2016-11-16 10:47 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article, which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Telbivudine <i>vs</i> tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zahari Krastev, Diana Petrova, Iskren Kotzev, Mustafa Kemal Celen, Meryl Mendelson, Richa Chandra, Priti Pandey and Kamal Hamed |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Novartis Pharma AG |
|
|
| Corresponding Author |
Kamal Hamed, MD, MPH, Sr Worldwide Medical Director, Novartis Pharmaceuticals Corporation,
1 Health Plaza, East Hanover, NJ 07936,
United States. kamal.hamed@novartis.com |
| Key Words |
Chronic hepatitis B; Glomerular filtration rate; Telbivudine; Tenofovir; Roadmap concept |
| Core Tip |
This was the first prospective, randomised, non-inferiority study in hepatitis B e antigen-negative chronic hepatitis B patients that compared telbivudine and tenofovir administered as per roadmap concept. Both treatments based on the roadmap approach were effective over a 156 wk treatment period. Non-inferiority of telbivudine arm to tenofovir arm was demonstrated at week 52, with over 91% of patients in each treatment arm achieving hepatitis B virus DNA level < 300 copies/mL. Both treaments showed acceptable safety profiles. Moreover, telbivudine showed an improvement in estimated glomerular filtration rate from baseline. |
| Publish Date |
2016-11-16 10:47 |
| Citation |
Krastev Z, Petrova D, Kotzev I, Celen MK, Mendelson M, Chandra R, Pandey P, Hamed K. Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study. World J Hepatol 2016; 8(32): 1402-1413 |
| URL |
http://www.wjgnet.com/1948-5182/full/v8/i32/1402.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v8.i32.1402 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
